News and Announcements
ZiggyLabs completes study which provides evidence of anti-cancer potential drugs for animals
- Published November 15, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ZiggyLabs are pleased to announce it has just completed a study which aimed to identify the mechanisms of actions of several lead candidate drugs observed to exhibit anti-tumour properties during our high-throughput drug screen.
Although each drug had a unique mechanism of action, reflecting the different molecular structures and direct targets of these drugs, all of the drugs studied were found to result in the increased expression of a protein which interacts with a second protein known to be the main driver of tumour progression.
This not only provides strong evidence that these drugs have anti-cancer potential, but also suggests that this protein may have utility as a direct drug target in this tumour type.
ZiggyLabs
ZiggyLabs, established in late 2016, is a boutique, R&D-focussed animal health company committed to winning the fight against cancer in dogs and cats. Currently, our focus is on developing therapies for hemangiosarcoma (HSA), a devastating, always-fatal blood malignancy with no effective treatment to date. We use a drug repositioning model, investigating existing drugs to identify their efficacy in cancer therapy.
Company Updates
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
Backed By Leading Investment Groups and Family Offices
